Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesPulmonologyAlaska Medicaid NIPPV Coverage Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentAlaska MedicaidPolicy N/A

    Home Non‑Invasive Ventilators (NIPPV) — Coverage Criteria (HCPCS E0466)

    Customize your policy alerts

    Sign up for all Alaska Medicaid policy alerts

    Know when Alaska Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Alaska Medicaid coverage and medical appropriateness criteria for home non-invasive ventilators (HCPCS E0466), who is eligible, and conditions considered not medically necessary or investigational.

    Policy Summary
    PayerAlaska Medicaid
    PolicyHome Non‑Invasive Ventilators (NIPPV) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2021
    Next Review DateN/A
    Key ActionObtain prior authorization for HCPCS E0466 and document that the patient meets the stated medical appropriateness criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    E0466covered device code when medically necessary
    3 monthsinitial authorization period for home NIPPV

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=45PaCO2 threshold for several indications
    >=52PaCO2 threshold for CPAP-failure COPD criteria
    O2<=88%sleep oximetry criterion

    Coverage and Medical Appropriateness Criteria

    inv-01: General home use eligibility

    Covered when ALL of the following are met

    General prerequisites: Individual is alert and oriented; able to cough or uses an assist device to clear secretions; absence of anatomic abnormality that precludes mask fitting, excessive secretions, and swallowing disorder.

    inv-02: Initial therapy — 3-month authorization

    Initial request for three (3) months is covered when ALL general prerequisites are met AND documentation shows ANY ONE of the listed diagnoses/criteria

    Diagnoses qualifying for initial NIPPV: Progressive neuromuscular disease, severe thoracic cage disorder, hypoventilation syndrome, or severe COPD resulting in respiratory insufficiency.

    Each diagnosis below requires the specific objective findings or symptoms listed.

    Progressive neuromuscular disease requirements: Documentation of symptoms characteristic of sleep-associated hypoventilation (daytime hypersomnolence, excessive fatigue, morning headache, cognitive dysfunction, or dyspnea).

    (Examples: muscular dystrophy, myasthenia gravis, polio, amyotrophic lateral sclerosis)

    Severe thoracic cage disorder requirements: Documentation of symptoms characteristic of sleep-associated hypoventilation (daytime hypersomnolence, excessive fatigue, morning headache, cognitive dysfunction, or dyspnea).

    (Examples: post-thoracoplasty for TB, fibrothorax, asphyxiating thoracic dystrophy)

    Hypoventilation syndrome requirement: Documentation of symptoms characteristic of sleep-associated hypoventilation plus an initial arterial blood gas PaCO2, done while awake and breathing the prescribed FIO2, greater than or equal to 45 mm Hg.PaCO2 >= 45 mm Hg
    Severe COPD-related requirements: Spirometry with FEV1 or FVC less than or equal to 70% PLUS documentation of ANY ONE of: (1) a PaCO2 measured during sleep or immediately upon awakening that is worsened by >= 7 mm Hg compared to the initial awake ABG, or (2) sleep testing showing oxygen saturation <= 88% for >= 5 minutes of nocturnal recording time (minimum recording time 2 hours) that is not caused by obstructive upper airway events (AHI < 5). Obstructive sleep apnea must be ruled out as the predominant cause.FEV1 or FVC <= 70%; PaCO2 delta >= 7 mm Hg; Sleep O2 <= 88% for >= 5 min (min 2-hr record)

    inv-03: Continuation therapy after initial 3 months

    Continued home use covered if ALL of the following are documented

    Continuation requirements: A signed and dated statement from the prescribing provider completed no sooner than 61 days after initiating use stating that evaluation has been completed; the recipient is compliant as evidenced by the provider's documented review of device usage data; and the recipient is benefiting from its use.

    Statement must be dated no sooner than 61 days after initiation.

    Alaska Medicaid does not cover non-invasive ventilators when used to treat obstructive sleep apnea. The policy states that non-invasive ventilators for the treatment of obstructive sleep apnea are considered not medically necessary. In addition, devices provided to Alaska Medicaid recipients must have FDA approval specific to the indicated use; devices lacking such approval for the specific indication are considered investigational and may be denied.

    Use of non-invasive ventilators for obstructive sleep apnea is explicitly classified as not medically necessary under this policy and therefore is not eligible for authorization or coverage.

    Coding and Clinical Thresholds

    Covered HCPCS when criteria metHCPCSCovered
    E0466Non-invasive ventilator
    inv-07: Arterial blood gas PaCO2
    PaCO2 threshold for most qualifying indications>= 45 mm Hg measured on arterial blood gas while awake and breathing prescribed FIO2
    PaCO2 threshold after CPAP failure for COPD>= 52 mm Hg measured on arterial blood gas while awake and breathing prescribed FIO2
    Context of usePaCO2 criteria apply as documentation of respiratory insufficiency for hypoventilation syndrome, thoracic cage disorders, and many COPD indications
    inv-08: Sleep oximetry
    Oxygen saturation criterionOxygen saturation <= 88% for >= 5 minutes of nocturnal recording time
    Minimum recording timeMinimum nocturnal recording time of 2 hours

    Provider Requirements and Prior Authorization

    Prior Authorization

    Prior authorization required for E0466

    Prior authorization is required for HCPCS code E0466; Alaska Medicaid will authorize non-invasive ventilators when medical appropriateness criteria are met.

    • Submit prior authorization for HCPCS E0466 before dispensing or billing.
    Step Therapy

    Documented CPAP trial and failure required for COPD indications

    For COPD-related indications when CPAP has been tried, documentation must show the member was compliant with CPAP and that CPAP failed to relieve symptoms, improve awake hypercapnia, and/or correct nocturnal arterial oxygen desaturation before NIPPV is authorized.

    • Verify CPAP compliance and document failure to relieve symptoms or gas exchange abnormalities (e.g., awake hypercapnia or nocturnal desaturation).
    • Include ABG and/or sleep oximetry results per COPD criteria when demonstrating CPAP failure.

    Background

    A non-invasive positive pressure ventilator (NIPPV) delivers ventilatory support through a non-invasive interface such as a nasal or face mask. These devices provide positive pressure ventilation to assist or replace spontaneous breathing and may be used acutely to reduce morbidity and mortality, during weaning from invasive ventilation, or in the home setting for chronic respiratory insufficiency after the patient is stabilized.

    Alaska Medicaid authorizes home use of NIPPV (HCPCS E0466) only when medical appropriateness criteria are met, and testing results are obtained while the individual is in a chronic stable state. Devices must have FDA approval specific to the indicated use to be considered for coverage.

    Definitions

    inv-16: NIPPV — definition and interfaces
    DefinitionNon-invasive positive pressure ventilator (NIPPV) provides ventilatory support through a non-invasive interface such as a nasal or face mask
    Typical interfacesNasal mask or full face mask (non-invasive interfaces)
    Intended usesProvides ventilatory support in acute settings and for home use in chronic respiratory insufficiency after stabilization
    Policy Summary
    PayerAlaska Medicaid
    PolicyHome Non‑Invasive Ventilators (NIPPV) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2021
    Next Review DateN/A
    Key ActionObtain prior authorization for HCPCS E0466 and document that the patient meets the stated medical appropriateness criteria.
    SourceLink
    On This Page
    Coverage and Medical Appropriateness CriteriaCoding and Clinical ThresholdsProvider Requirements and Prior AuthorizationBackgroundDefinitions
    Testing conditionsDone while breathing the prescribed FIO2 (or while on oxygen at 2 LPM or prescribed FIO2 when specified) and not caused by obstructive events when applicable
    inv-09: Spirometry
    Spirometry thresholdFEV1 or FVC <= 70%
    Use in COPD criteriaRequired as part of COPD-related documentation for initial NIPPV eligibility
    Reference test typeForced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC)
    inv-10: Maximal inspiratory pressure / FVC
    Maximal inspiratory pressure (MIP)MIP < 60 cm H2O
    Forced vital capacity (FVC)FVC < 50% predicted
    Role in eligibilityEither MIP or FVC criterion qualifies as objective evidence of respiratory muscle weakness or reduced lung volumes for NIPPV candidacy
    Documentation Required

    Required clinical and objective documentation

    Include documentation showing the patient meets the listed medical appropriateness criteria, including clinical symptoms and objective testing such as arterial blood gas, spirometry, sleep oximetry, or polysomnography; for continuation after the initial 3 months include a signed, dated provider statement (no sooner than 61 days after initiation) documenting evaluation, device usage review, compliance, and benefit.

    • Clinical documentation of symptoms (e.g., daytime hypersomnolence, excessive fatigue, morning headache, cognitive dysfunction, dyspnea) where applicable.
    • Objective tests as required by diagnosis: ABG (PaCO2 thresholds), spirometry (FEV1 or FVC ≤ 70%), sleep oximetry (O2 ≤ 88% for ≥5 minutes; min 2-hour recording), or polysomnography.
    • For continuation: signed and dated statement from prescribing provider completed no sooner than 61 days after initiation confirming evaluation, documented review of device usage data showing compliance, and evidence of benefit.
    Denial Risk

    Denial triggers: OSA treatment and non‑FDA‑approved uses

    Requests for non-invasive ventilators to treat obstructive sleep apnea are considered not medically necessary; devices lacking FDA approval specific to the indication are investigational and may be denied.

    • Do not submit NIPPV requests for primary treatment of obstructive sleep apnea — these will be denied as not medically necessary.
    • Confirm device has FDA approval specific to the intended indication; devices without such approval are investigational and at risk for denial.